-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Systemic immunomodulators used to treat atopic dermatitis include cyclosporine, methotrexate, azathioprine, mycophenolate mofetil, and dupilumab, abrutinib, braziltinib, tralotinib Kinumab and upadacitinib were recently approved in different countries
.
There are few face-to-face trials of these drugs, making direct comparisons of efficacy and safety difficult
Since October 2019, 21 new studies have been added for a total of 60 trials with a total of 16 579 patients
.
Adults treated for up to 16 weeks, abrocitinib, 200 mg daily (mean difference [MD], 2.
Our study found that acrotinib 200 mg daily and upadacitinib 30 mg daily may have slightly higher index scores than dupilumab 600 mg and 300 mg biweekly
.
Our results may help clinicians understand the differences between different treatment options for moderate-to-severe atopic dermatitis
Source: Drucker AM, Morra DE, Prieto-Merino D, Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis.
leave a message here